1,615 results on '"Ratain, Mark J."'
Search Results
152. The Right Dose: From Phase I to Clinical Practice
153. The Abiraterone Dosing Chess Match With Johnson & Johnson—Back in Check
154. A phase I study of continuous infusion cilengitide in patients with solid tumors
155. The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
156. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial
157. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
158. Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)
159. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver
160. The development of a financial toxicity patient-reported outcome in cancer: The COST measure
161. Genome-wide Interrogation of Longitudinal FEV1 in Children with Asthma
162. TARGETED THERAPIES: Redefining the primary objective of phase I oncology trials
163. Re: Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA
164. Vemurafenib oral bioavailability: An insoluble problem
165. Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project”
166. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551
167. The Werner’s syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds
168. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
169. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
170. Integration of a polygenic risk score of kidney function with cumulative cisplatin dose and time variables for the prediction of serum platinum levels.
171. Patient out-of-pocket savings with lower-dose trastuzumab.
172. Influence of N ‐acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib
173. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments
174. Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer
175. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer
176. sj-pdf-1-tam-10.1177_1758835920974118 – Supplemental material for Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial
177. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study
178. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity
179. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer
180. Pharmacokinetic variability of anticancer agents
181. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor
182. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
183. Ibrutinib’s Cardiotoxicity—An Opportunity for Postmarketing Regulation
184. Oncology’s “Hockey Stick” Moment for the Cost of Cancer Drugs—The Climate Is About to Change
185. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)
186. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases
187. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors
188. A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer
189. Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)
190. COVIDOSE: A Phase II Clinical Trial of Low‐Dose Tocilizumab in the Treatment of Noncritical COVID‐19 Pneumonia
191. Pharmacogenomics: road to anticancer therapeutics nirvana?
192. Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors
193. Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science
194. Preventing Adverse Drug-Drug Interactions: A Need for Improved Data and Logistics
195. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment
196. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer
197. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil
198. In Vitro Characterization of Hepatic Flavopiridol Metabolism Using Human Liver Microsomes and Recombinant UGT Enzymes
199. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice
200. Oncology Drug Prescribing: The Influences of Greed and Fear
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.